Trial Profile

A Phase I, Open-label, Fixed-sequence, Crossover, Drug-drug Interaction Study to Investigate the Inhibition Potential of KL1333 on CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, and CYP3A4 in Healthy Subjects

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 22 Oct 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs KL 1333 (Primary) ; Bupropion; Caffeine; Dextromethorphan; Flurbiprofen; Midazolam; Omeprazole; Repaglinide
Indications Diabetes mellitus; Mitochondrial disorders
Focus Pharmacokinetics; Proof of concept
Sponsors Abliva

19 Oct 2021 Status changed from recruiting to completed.
03 Dec 2020 New trial record
20 Nov 2020 According to an Abliva media release, company doses the first healthy volunteers in the company's drug-drug interaction study (DDI study) with KL1333.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com